Pranav Shrestha

Pranav Shrestha

Auto-generated profile, based on publicly available information

Pranav Shrestha

Department of Mechanical Engineering, The University of British Columbia, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
LWLibo Wu
Libo Wu
PSPranav Shrestha
Pranav Shrestha
MIMartina Iapichino
Martina Iapichino
YCYicheng Cai
Yicheng Cai
BKBeomjoon Kim
Beomjoon Kim
BBBoris Boris
Boris Boris

1 January 2020 in Physics of Fluids
Verified
Journal Article
Open access
PDF file
PSPranav Shrestha
Pranav Shrestha
BBBoris Boris
Boris Boris
One of the most common health care procedures is injecting fluids, in the form of drugs and vaccines, into our bodies, and hollow microneedles are emerging medical devices that deliver such fluids into the skin. Fluid injection into the skin through microneedles is advantageous because of improved patient compliance and the dose sparing effect for vaccines. Since skin tissue is a deformable porous medium, injecting fluid into the skin involves a coupled interaction between the injected fluid flow and the deformation of the soft porous matrix of skin tissue. Here, we introduce a semiempirical model that describes the fluid transport through skin tissue based on experimental data and constitutive equations of flow through biological tissue. Our model assumes that fluid flows radially outward and tissue deformation varies spherically from the microneedle tip. The permeability of tissue, assumed to be initially homogeneous, varies as a function of volumetric strain in the tissue based on a two-parameter exponential relationship. The model is optimized to extract two macroscopic parameters, k0 and m, for each of the seven experiments on excised porcine skin, using a radial form of Darcy’s law, the two-parameter exponential dependence of permeability on strain, and the experimental data on fluid flow recorded by a flow sensor and tissue deformation captured in real time using optical coherence tomography. The fluid flow estimated by the permeability model with optimized macroscopic parameters matches closely with the recorded flow rate, thus validating our semiempirical model.

1 August 2023 in Physics of Fluids
Verified
Journal Article
Open access
PDF file
MWMary-Jo Weir Weiss
Mary-Jo Weir Weiss
PSPranav Shrestha
Pranav Shrestha
RBRaunak Basak
Raunak Basak
BBBoris Boris
Boris Boris
Better understanding of skin tissue's permeability and poroelasticity could help advance biomedical technologies concerning skin such as intradermal injection and grafting. We applied a pressure driven fluid flow across skin tissue's epidermal and dermal layers in a simple one-dimensional configuration, while measuring the resulting flow rate and capturing cross sectional optical coherence tomography (OCT) images of the tissue's deformation. Digital image correlation was used to analyze the OCT images and via a novel method, image analysis corrected for the change in the tissue's refractive index, which occurred due to flow-induced deformation, thus providing accurate one-dimensional depth-wise deformation profiles. Skin tissue was found to exhibit a nonlinear relationship between pressure and the resulting fluid flow rate, where the increase in flow rate with pressure decreased as pressure increased. The skin tissue was observed to experience compressive strain closest to the supported base, with magnitudes increasing with increasing driving pressure, and the tissue near the free surface experienced relatively little strain. Permeability was found to follow an exponential permeability-volumetric strain relationship with material constants: k0 (initial uniform permeability) of 9.6 × 10−15 m2 and m (extent of nonlinearity for the permeability–strain relationship) of 2.94. Darcy's law and the permeability–strain relationship were used to analyze results with good similarity between observed and calculated flowrates. This work presents a novel and direct method of characterizing soft tissue permeability and provides a fundamental understanding to skin behavior under pressurized driving fluid, which can be generalized to study or model other geometries of induced flow through skin tissue.

17 June 2024 in Soft Matter
Verified
Journal Article
Closed access
PDF file
PSPranav Shrestha
Pranav Shrestha
CGCurtis Geffner
Curtis Geffner
MJMatthew Jaffey
Matthew Jaffey
ZWZhongnan Wu
Zhongnan Wu
MIMartina Iapichino
Martina Iapichino
BBBoris Boris
Boris Boris
Several medical applications, like drug delivery and biosensing, are critically preceded by the insertion of needles and microneedles into biological tissue. However, the mechanical process of needle insertions, especially at high velocities, is currently not fully understood. Here, we explore the insertion of hollow needles into transparent silicone samples with an insertion velocity v ranging from 0.1 mm s−1 to 2.3 m s−1 (with needle radius R = 101.5 μm, thus strain rates ∼v/R ranging from 1 s−1 to 2.3 × 104 s−1). We use a double-insertion method, where the needle is inserted and re-inserted at the same location, to estimate the fracture properties of the material. The deflection of the specimen's free surface is found to be different between insertion and re-insertion experiments for identical needle positions, which is associated with different force magnitudes between insertion/reinsertion. This aspect was previously neglected in the original double-insertion method, thus here we develop a method based on imaging, image analyses and force measurements to decompose the measured force into individual force components, including deflection force Fd, frictional and spreading force Ff + Fs, and cutting force Ft. We estimate that the toughness Γ of our silicone samples, calculated using the cutting force Ft and the crack dimensions, increases with needle velocity, and ranges within observed values in previous literature for the same material and for some soft biological materials. In addition to toughness Γ, other parameters, such as critical force Fc and mechanical work Wc, also show strain-rate dependence, suggesting tissue stiffening, due to accumulated strain energy, at high speeds.

1 April 2025 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
PSPranav Shrestha
Pranav Shrestha
HLHendrik Lohse
Hendrik Lohse
CBChristopher Bhatla
Christopher Bhatla
HMHeather McCartney
Heather McCartney
AAAlaa Alzaki
Alaa Alzaki
BBBoris Boris
Boris Boris
Sickle cell disease (SCD) persists as a major global health problem, disproportionately affecting children in low- and middle-income countries (LMIC). Accurate and low-cost point-of-care techniques are urgently needed in LMIC to detect carrier or disease forms with haemoglobin S (HbS) and other variants like β-thalassemia. An open-label, international, multicentre study was conducted at clinical sites in Nepal and Canada. Blood samples were collected from healthy volunteers (HbAA) and participants with known haemoglobinopathies (HbA/β-thalassemia, HbAS, HbS/β-thalassemia, HbSS). The performance of six low-cost tests (Conventional sickling test; HbS solubility test; HemoTypeSC; Sickle SCAN; Gazelle Hb variant test; Automated sickling test using automated microscopy and machine learning) was evaluated against HPLC (ClinicalTrials.gov Identifier: NCT05506358). Between September 2022 and March 2023, we enrolled 138 participants (aged 2-74 years; 59% female, 41% male) at clinical sites in Nepal and Canada. Four low-cost tests (HemoTypeSC, Sickle SCAN, Gazelle, and automated sickling), which could identify phenotypes, detected severe SCD (HbSS, HbS/β-thalassemia) accurately (sensitivity >96%; specificity >99%). In contrast, for carrier forms, HemotypeSC and Sickle SCAN only detected HbAS (sensitivity >97%; specificity 100%) and not HbA/β-thalassemia (sensitivity 0%; specificity 100%), while Gazelle detected HbAS (sensitivity 100%, specificity 100%) and HbA/β-thalassemia (sensitivity 91%, specificity 99%), and automated sickling test detected both trait conditions (HbAS and HbA/β-thalassemia; sensitivity 85%, specificity 85%). When HbS co-exists with β-thalassemia, Gazelle and automated sickling test accurately identify severe SCD and carrier forms. However, HemotypeSC and Sickle SCAN miss β-thalassemia trait, and need to be complemented with other low-cost tests. UBCPSI, Canada Research Chairs, UBC HIFI Awards, UBC 4YF, Naiman Vickars Endowment fund.

23 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
PSPranav Shrestha
Pranav Shrestha
HLHendrik Lohse
Hendrik Lohse
CBChristopher Bhatla
Christopher Bhatla
HMHeather McCartney
Heather McCartney
AAAlaa Alzaki
Alaa Alzaki
BBBoris Boris
Boris Boris
Sickle cell disease (SCD) and β-thalassemia are the most common monogenic diseases, disproportionately affecting low- and middle-income countries, where low-cost and accurate diagnostic tools are needed to reduce the global disease burden. Although the sickling test is commonly used to screen for the sickle mutation, it cannot distinguish between the asymptomatic sickle cell trait (SCT) and SCD, or identify β-thalassemia. Here, we enhanced the inexpensive sickling test using automated microscopy and morphology-based machine learning classification to detect SCD, trait conditions (SCT and β-thalassemia trait) and normal individuals with an overall area under receiver operating curve, sensitivity and specificity of 0.940 (95% confidence intervals: 0.938-0.942), 84.6% (84.2%-84.9%), and 92.3% (92.1%-92.4%), respectively. Notably, the sensitivity and specificity to detect severe disease (SCD) was over 97% and 98%, respectively, thus establishing a low-cost automated screening option for disease detection in low-resource settings. Furthermore, leveraging high-throughput microscopy, we generated an open-access dataset comprising over 300,000 images with 1.5 trillion segmented cells from 138 individuals in Canada and Nepal including individuals with sickle and/or β-thalassemia mutations, to accelerate further research.